On April 7, 2022 Sequence Bio, a Newfoundland and Labrador-based discovery biology company, reported that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio’s proprietary discovery platform to identify novel dermatologic drug targets (Press release, Leo, APR 7, 2022, View Source [SID1234611620]). Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insights generated under this collaboration to build robust evidence in support of new potential approaches that significantly impact dermatologic conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to enter this collaboration agreement with Sequence Bio to further accelerate LEO Pharma’s ambition to identify novel dermatologic drug targets," said Thorsten Thormann, Vice President of Research & Early Development in LEO Pharma. "LEO Pharma is relentlessly committed to making pioneering advances in dermatology research and bringing new treatments to patients faster."

"We are excited to work with LEO Pharma on their mission to positively impact millions of lives through medical dermatology," said Dr. Richard Leach, Chief Strategy Officer of Sequence Bio. "This collaboration aligns with our strategic priorities to expand the potential of our discovery platform to power life-changing medicines in areas of unmet medical need across the globe."